Nanostics is a commercial-stage company revolutionizing healthcare decisions through artificial intelligence and machine learning. Nanostics is seeking to raise $15 million USD to fund North American sales and expansion into global markets for its lead product ClarityDX Prostate. ClarityDX Prostate is on track to become the first Software as a Medical Device (SaMD) for prostate cancer screening creating a disruptive new SAAS-like business model that is highly scalable.

Nanostics’ lead product, ClarityDX Prostate, is being used across Canada and was recently launched in the US to more accurately identify men with clinically significant prostate cancer and reduce the number of unneeded biopsies.